Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... with Novella Clinical (Novella), to conduct the ... newly diagnosed glioblastoma. Novella is a full-service, global clinical ... to mid-sized oncology companies. The ICT-107 phase 3 trial ... Europe and Canada ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... 28 RainDance Technologies, Inc.,a developer of ... of Christopher McNary as President and Chief,Executive ... of the,Board, in driving RainDance Technologies, vision ... Laboratory System in the Life,Sciences and other ...
... &,Instrumentation (CRi) announced today that the United States ... their patent application number,10/669,101, for Spectral Imaging of ... use of multispectral imaging combined,with spectral unmixing to ... living mammal. The unmixing of tissue autofluorescence is,a ...
... 28 Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced ... will participate in the BMO,Capital Markets Focus on Healthcare ... Broadway Hotel in New York, NY. Dr. Hudson,s,presentation at ... a.m. ET., Dr. Hudson will present a company ...
Cached Biology Technology:RainDance Technologies Appoints McNary President and CEO 2RainDance Technologies Appoints McNary President and CEO 3US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue 2Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference 2
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... It makes me sad when an article that should have ... of the student's group in the iGEM competition , check ... their bacterial 'camera'. , Using Petri dishes full of ... The University of Texas at Austin and UCSF successfully created ...
... at the Albert Einstein College of Medicine and the ... is targeted to certain regions of a cell--a process ... wound healing and cancer metastasis. Their study appears in ... Led by Drs. Robert Singer and Dr Stefan Huettelmaier, ...
... researchers has discovered that human embryonic stem cell lines accumulate ... findings do not limit the utility of the cells for ... the researchers say, but draw attention to the need to ... study how these alterations affect the cells' behavior. The researchers' ...
Cached Biology News:Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2Embryonic stem cells accrue genetic changes 2Embryonic stem cells accrue genetic changes 3Embryonic stem cells accrue genetic changes 4
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: